The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s ...

Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast ...

Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by ...

Seaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a ...

News of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an ...

A strong performance from Mounjaro overseas boosted Lilly’s results, and the company raised its guidance for the year for ...

Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that ...

The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and ...

Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, ...

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...

Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology ...

Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from ...